Key Highlights
● Kodiak Sciences (KOD) closed at $89.92 on Monday, up about 178% from $32.35, after positive Phase 3 DAYBREAK results.
● Both Zenkuda and tabirafusp-ted met their primary endpoints in wet age-related macular degeneration against aflibercept, according to the company.
● About 54% of Zenkuda patients were on a six-month dosing interval at year one, and no intraocular inflammation was reported.
● The company plans a multi-indication Biologics License Application for Zenkuda in the fourth quarter of 2026.
Kodiak Sciences (NASDAQ:KOD) surged on Monday, September 28, closing at $89.92 against $32.35 on Friday, a gain of about 178%. The stock opened near $61.71, touched an intraday high of $95.77 and held most of the move into the close, according to market data. The catalyst was topline data from DAYBREAK, a pivotal Phase 3 trial in wet age-related macular degeneration, a leading cause of vision loss in older adults.
What DAYBREAK Showed
Kodiak said both of its drugs, Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501), met the trial's primary vision endpoint against aflibercept, a widely used standard treatment. The company reported p-values of 0.0007 for Zenkuda and 0.0036 for tabirafusp-ted. A p-value below 0.05 is the usual bar for statistical significance. Tabirafusp-ted also met a key anatomical secondary endpoint.
On safety, Zenkuda showed no intraocular inflammation, and cataract events were 0.5% against 0.9% for aflibercept, according to the release. Chief executive Victor Perlroth said the data position the company for the commercialisation of Zenkuda. For tabirafusp-ted, intraocular inflammation was 0.4% against 0.9% for aflibercept, and cataract events were 0% against 0.9%, according to the release. Both drugs were described as consistent with the established safety profile of aflibercept.
Why Investors Cared
Wet macular degeneration is usually managed with repeated eye injections. Kodiak said 54% of Zenkuda patients were on a six-month dosing interval at year one, using strict retreatment criteria. A drug that matches standard care with fewer visits could matter to patients and clinics, though real-world uptake will depend on regulators, pricing and competition. The company described Zenkuda as having a potential new standard-of-care profile, a claim regulators and doctors have yet to test. The move lifted the company's Market Value above $5 billion, according to market data.
A Rare Bright Spot
Major indexes closed in the red. The S&P 500 declined 59.72 points to 7,683.69, the Dow Jones Industrial Average slid 347.11 points to 51,481.51, and the Nasdaq Composite retreated 248.34 points to 26,820.38. Rates did much of the damage. The 10-year Treasury Yield touched its highest level since 2007, and the 30-year hit its highest since 2004, which weighed on richly valued shares. Health care was one of the few S&P 500 sectors to finish higher, according to market reports, which gave biotech a friendlier backdrop.
What to Watch for Kodiak Sciences
Kodiak plans to file a multi-indication Biologics License Application for Zenkuda in the fourth quarter of 2026, covering wet macular degeneration, diabetic retinopathy and retinal vein occlusion. The company also expects topline data from its Phase 3 PEAK study of KSI-101 in December 2026.
After a one-day jump this size, Volatility often stays high as early holders sell and new buyers step in. Macro data will steer the week. Tuesday brings JOLTS and consumer confidence, Wednesday the PCE Inflation reading, Thursday the ISM Manufacturing survey and Friday the September employment report.






Please wait processing your request...